The inclusion of younger men in active surveillance (AS) is still under debate. Our aim was to assess potential differences in incidence, the reason for discontinuation and treatment choice between men under 60 years (< 60) and men between 60 and 70 years (! 60-70) within the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database.
INTRODUCTION AND OBJECTIVES:
The inclusion of younger men in active surveillance (AS) is still under debate. Our aim was to assess potential differences in incidence, the reason for discontinuation and treatment choice between men under 60 years (< 60) and men between 60 and 70 years (! 60-70) within the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database.
METHODS: The GAP3 initiative has the largest centralized PCa AS database to date including data of over 15,000 men. We compared data from 3353 (29%) men < 60 and 8177 (71%) men ! 60-70 at time of starting AS, excluding unknowns and men over 70 yrs (N [ 3571 men). Characteristics at time at inclusion were compared and cumulative incidence curves were used to estimate rates of AS discontinuation and treatment choice.
RESULTS: Younger men opting for AS have lower PSA at diagnosis (median 4.8, IQR 3.5 -6.4 ng/ml) than older men (median 5.4, IQR 4.1 -7.2 ng/ml), and 75% of men < 60 have cT1 PCa compared to 72% in men ! 60-70. At 1 at 5 years respectively, 6% and 38% of men < 60 have stopped AS compared to 8% and 43% of men ! 60-70 ( Figure 1A-B) . After 1 year on AS, 5% of men in both age groups opted for a switch to curative treatment ( Figure 1C-D) , with equal proportion of men in both age groups opting radical prostatectomy (RP) and radiotherapy (RT). Within both age groups, most men opted for RP. Of the men who underwent RP in the available follow-up, 186 (30%) of men < 60 year and 437 (33%) men ! 60 and 70 experienced adverse pathology on RP (i.e., ! pT3, or pT2 with positive surgical margins, or Nþ, or pathological Gleason ! 4þ3).
CONCLUSIONS: Our descriptive analysis of current AS practices worldwide show that taking into account a peak incidence at ! 60-70 still younger men opting for AS are in minority. This likely reflects the fear of missing progression to clinically significant PCa. The outcomes with respect to discontinuation, reclassification, and adverse pathology on RP are however comparable confirming that AS seems to be a safe treatment option for younger men (Mahran et al., Urology 2018).
Source of Funding: This work was supported by the Movember Foundation. The funder did not play any role in the study design, collection, analysis or interpretation of data, or in the drafting of this paper.
MP48-05 COMPARATIVE OUTCOMES OF GLEASON GRADE 2 AND 3 PROSTATE CANCER ON INITIAL VERSUS CONFIRMATORY BIOPSY: IMPLICATIONS FOR ACTIVE SURVEILLANCE
Samuel Haywood*, Amy Tin, James Eastham, Vincent Laudone, Karim Touijer, Peter Scardino, Andrew Vickers, Behfar Ehdaie, New York, NY INTRODUCTION AND OBJECTIVES: Among men with low risk prostate cancer (PCa) managed with active surveillance (AS), upgrade to Gleason Grade Group (GG) !2 has been used to trigger treatment. We aimed to compare the outcomes of men with GG2/3 PCa undergoing immediate radical prostatectomy (RP) with men who initially met AS eligibility but were upgraded on confirmatory biopsy and subsequently underwent RP.
METHODS: We retrospectively reviewed a prospectively maintained database of men who were treated with RP at Memorial Sloan Kettering Cancer Center from 2000 to 2016. Two cohorts were selected: an "immediate RP" group with GG 2/3 PCa treated initially (within 6 months of diagnostic biopsy) and a second group of men initially eligible for AS ("AS group") with GG1 but upgraded to GG2/3 on confirmatory biopsy within 12 months. We compared probabilities of biochemical recurrence (BCR) and salvage therapy using two separate multivariable Cox regression models, with risk-adjustment by a nomogram predicting preoperative BCR. Rates of adverse pathology were also compared, utilizing two definitions varying on inclusion of extracapsular extension (ECE).
RESULTS: We identified 4011 patients in the immediate RP group and 321 patients in the AS group. Overall, 789 patients experienced a BCR with median follow-up of 3.9 years in BCR-free survivors. BCR risk was lower in men upgraded on confirmatory biopsy, although differences did not meet statistical significance (hazard ratio, HR 0.73; 95% CI 0.50, 1.06; p[0.10; rates at one-year (6.2% vs. 4.6%) and three-years (16% vs. 8.1%); Figure) . Results were similar for salvage-treatment-free survival (HR 0.67, 95% CI 0.42, 1.06, p-value [ 0.088), with estimated rates in the AS and immediate RP groups at one-year as 2.8% vs. 4.2% and three-years as 5.4% vs. 12%. The AS group had significantly lower rates of adverse pathology, excluding ECE (27% vs. 35%, p[0.003).
CONCLUSIONS: We found evidence that men with low-risk prostate cancer upgraded on confirmatory biopsy have better outcomes than men with identical tumors found at initial biopsy. These results would need to be confirmed in other and larger series before we counsel men that upgrading on confirmatory biopsy does not portend the same prognosis as a high-grade tumor found on initial biopsy. 
